From FDA to PMI – a sell-out or a bold move for public health?

Matt Holman resigns as Director of the Office of Science at the Center for Tobacco Products at the FDA. He is moving to the tobacco company Philip Morris International to be Vice President of US Scientific Engagement & Regulatory Strategy. What to make of this? I write him an open letter.

Dear Dr Holman

You are making an interesting move at an important time, and I want to write an open letter to you to remark on its significance.

I am sure many will criticise your move as treachery or a sell-out, but this is a predictable knee-jerk reflex and overlooks the public health fundamentals. I hope you ignore the inevitable criticism and remain focused on the enormous public health prize that you can pursue in your new role. I think it is an ethical and high-integrity move, and I hope you make the most of it.

The case for moving from FDA to a tobacco company

How can anyone pursue a public health goal effectively from a tobacco company?

In reality, we are in the formative phase of a fundamental and highly beneficial technology transformation in the consumer market for nicotine. This is the move from high-risk combustible products (cigarettes) to low-risk non-combustibles (vaping, heated and smokeless tobacco, and oral nicotine products such as pouches). This is a game-changer for public health.

I know many employees at PMI and the other major tobacco companies whose only mission is to expedite that transition, and you will be joining them in a big leadership role. In terms of its potential to reduce the burden of death and disease in the United States and worldwide, this transformation is probably the most significant technology change of the coming decades. Literally, millions of lives – maybe hundreds of millions globally – are on the line.

We have met several times at conferences, and I believe that you are sincerely focused on the public health goal of eliminating the burden of misery, disease and death caused by smoking. You have been immersed in the science in this field and have concluded that major public health gains can be made by large numbers of smokers switching from cigarettes to non-combustible products. You are one of the highest profile regulatory professionals to understand that potential, and your career move amounts to a very significant endorsement of this approach. I doubt you would be making this move if you did not see the public health opportunity in pursuing that strategy. I share your optimism about this.

Your move to a tobacco company will surprise or even shock many. But they should not be shocked or surprised. They misunderstand how a major technology transformation will come to pass. The tobacco companies will be prime movers in making this work globally. They will innovate (or acquire innovation) to respond competitively to growing consumer demand for safer products. They will be guided by the incentives created by the regulatory, fiscal and information environments in which they operate. These companies can slow or expedite progress, but so can regulators, tax authorities, politicians, academics and tobacco control advocates. There is everything to play for in getting this transition right. I hope all the companies will be proactive in shaping the incentive structure in which they operate to expedite a pro-health transformation of the nicotine market, and I believe this is the reason you have been hired.

In its 2021 investor presentation, PMI said the following:

The company … believes that with the right regulatory frameworks, dialogue and support from civil society, cigarette sales can end within 10 to 15 years in many countries.

PMI press release, February 10, 2021

I agree with this. And what a great goal to pursue as a career professional.

The objections to moving from FDA to a tobacco company

What about the objections to your move? I will list four and give my view on them.

A. Harm reduction is the nicotine maintenance strategy of Big Tobacco

The alternative to trying to end cigarette sales is to pursue a nicotine-free society. This goal is increasingly embraced implicitly and sometimes explicitly in the tobacco control community. In my view, this is a misguided Utopian idea underpinned by a war-on-drugs mindset. It has made too many in tobacco control indifferent to the huge variations in risk between nicotine products – what the FDA sometimes describes as the continuum of risk. This leads to ad hoc and unstrategic advocacy – taking the approach of eliminating every nicotine product possible whenever the opportunity arises. This is a bad strategy, as it will protect the incumbent cigarette trade and prolong the burdens of smoking and related harms. There might be something positive to say about this if the ‘endgame’ for nicotine was within reach, but I don’t believe it is.

I think the endgame for smoking is within reach, but the demand for nicotine is far more robust. This is because, for some people, nicotine has functional and pleasurable effects, and there will be a permanent demand for this drug. Neal Benowitz, a global authority on nicotine, writing in 2009, summarised the effects:

In humans, nicotine from tobacco induces stimulation and pleasure, and reduces stress and anxiety. Smokers come to use nicotine to modulate their level of arousal and for mood control in daily life. Smoking may improve concentration, reaction time, and performance of certain tasks.

Benowitz, N. L. (2009). Pharmacology of Nicotine: Addiction, Smoking-Induced Disease, and Therapeutics. Annual Review of Pharmacology and Toxicology, 49, 57. [link]

The public health challenge is to dramatically reduce the harm to people who wish to use this stimulant or find it useful. That harm is caused by the method of delivery, overwhelmingly smoking, not by the relatively innocuous but highly-valued effects of the drug itself.

B. PMI is still a huge cigarette maker

A company like PMI cannot stop selling cigarettes while there is still a market for them and while it is a legal supplier in that lawful, regulated and taxed market established by governments. That’s what a tobacco company does, by definition. If it tried to stop, its shareholders would revolt, its management would be fired, the company would be taken over, and the productive assets and intellectual property sold. It would achieve nothing, and it is pointless to call for it.

Instead of flaunting tobacco warrior credentials, we need to concentrate on what will cause actual change. We should adopt the perspective of clear-eyed strategists with an aim to eliminate as much harm as possible as quickly as possible. That would tell us that a pro-health transformation of the nicotine market is possible and desirable.

What a company can do is change the nature of the market through product R&D and innovation, marketing efforts, and regulatory and scientific engagement. It can do its utmost to move the market and to win market share for its low-risk products from smokers of its own brands and those of competitors – thus combining a public health gain with a competitive strategy.

This means we should judge these companies not on where they have come from and the behaviours of the past, though these should never be forgotten. We should judge them by their meaningful efforts to change and the direction they are trying to follow. The past is settled. What they are doing now and where they are heading is what matters. I think the international tobacco companies understand this and where their market is heading and are changing accordingly.

The problem is the “Bootlegger and Baptist” alliance between the dinosaurs of the global tobacco industry (especially the state-owned monopolies) and the dinosaurs of the tobacco control community, as they work tirelessly to obstruct a pro-health transformation. They are proving themselves incapable of looking beyond their longstanding animus towards “Big Tobacco”, which is not, and never, was monolithic and singular in its approach. The facts have changed, and they will have to change too or find themselves marooned by reality.

C. Ruin the vape industry and join a tobacco company

One argument is that in your position at FDA, you have signed the death warrants of thousands of small businesses and vape shops (their Marketing Denial Orders), and now you want to work for the big companies that profit from the brutal barriers to entry imposed by FDA. As you know, I have been very critical of FDA’s approach to the smaller vaping companies and harm reduction in general. But the fact is you have resigned from FDA and moved out of the Federal government machinery to pursue harm reduction by different means. That is not something I expected, but it is certainly something I welcome.

I know from my own experience as a civil servant that bureaucracies are extremely difficult to shape in your own image, especially if you are not in overall control. They are fashioned from a thicket of competing pressures, rival ideas and visions, personal ambitions, moral intuitions and ideologies, risk-aversion, alliances and enmities, principal-agent relationships and mandates, legal interpretations, personal political orientations, scrutiny and accountability pressures, and human judgement. If you are cause-driven, the art of working in a bureaucracy is to shape it to the extent you can in the hope that you will make it better. But that is never easy and not always possible… and that can take some time to discover.

My view is that FDA/CTP has made a set of bad policy choices about low-risk products. It failed to create a viable and proportionate regulatory regime for the thousands of low-risk products. It was too susceptible to the national moral panic over youth vaping and lost sight of the bigger picture: that being the means to drive down adult smoking. At the same time, FDA faced intense political pressure from a well-financed complex of anti-tobacco and anti-vaping interests that wilfully distorts science, promotes major scares and is indifferent to the harmful consequences of quasi-prohibitions or excessive regulation. This is where I lay the blame.

But the result was that FDA did not explore the options to simplify and lessen the regulatory burdens imposed on vaping companies to anything like the extent necessary or possible under the Tobacco Control Act. We probably disagree about how much latitude FDA could have used if it wanted to, but I hope you will have more to say about this in your new role.

I don’t know what role you played in all this or what you could have done differently, and what effect, if any, that might have had. I am not going to be an apologist for FDA’s approach as it has very negative consequences. But neither do I think others should judge someone who has worked in a bureaucratic environment like this and tried to pursue public health objectives without as much success as they may have hoped. The point is that you are going to pursue the same agenda by different means, and that is the reason for your career move. I hope you will be an effective advocate for better policy and a better FDA, and we should all welcome that.

D. Conflicts of interest

Have you improperly moved from the regulator to the regulated? That is, from gamekeeper to poacher? I don’t think we should dwell on this for long. As I understand it, there are strict government guidelines about standing down when you begin a job search and staying apart for two years when you move from a government job to a business with significant interactions with the department you worked in. This sort of move is normal, given the skills overlap. I assume the rules were followed to the letter and in spirit. If anyone wishes to criticise, they should show the rules were not followed.

Some advice

Finally, some advice on the challenges ahead (whether you want it or not…). In your new role and with your new team and the new company, I would try to do some or all of the following (and I realise this is not all down to you):

  1. Do as much as you can to explain your personal rationale for this move and your view of THR and tobacco companies. There is a coherent, ethical and high-integrity logic to it that needs a wider understanding. Obviously, this is important for you personally, but it is also important for your colleagues, the companies more generally, and those of us in public health who want to see this market transformation work. This is about building trust.
  2. Develop an optimum regulatory, fiscal and communications package that would advance the transformation away from combustibles and build support for it among other nicotine companies, consumers, academics and public health professionals. This should shape the long-term direction and address issues like the place of nicotine in society, the embrace of innovation, the principle of proportionality, an appropriate balance between state intervention and user autonomy and, above all, clarity on goals.
  3. Take the high ground and think at the whole category level, taking account of the diversity of companies, products, consumers, and consumer preferences. I hope you will avoid the counterproductive strategy of trying to rig the market to favour PMI products at the expense of others. I have seen this approach from tobacco companies, and it will not work for anyone in the long run. There is plenty of scope for competition without trying to tilt the playing field.
  4. I would really like to see your ideas on how FDA could innovate to create a viable approach to pre-market authorisation, modified risk claims, and rule-making that puts the consumer interest first, including their interests in their own health. Also, if necessary, any legislative changes that are needed. There is no point or value in criticising FDA or anyone connected with it. What’s needed now are constructive ideas to lift the agency out of its chaotic state and into being a trusted, efficient, transparent and predictable regulator.
  5. Do more to address the tsunami of poor quality and sometimes malicious science that degrades and detracts from addressing the public health challenge. We all have interests in good quality science. I feel the companies have the deep expertise to do more to challenge junk science.

I appreciate this will take more than just your own efforts, but I hope that as a leader in the field taking on a new role, you can make some progress on this agenda.

Very best wishes for success in your new role.

Yours sincerely

Clive Bates

Download Post as PDF

18 thoughts on “From FDA to PMI – a sell-out or a bold move for public health?”

  1. While there have been articles lauding Dr. Holman as a well-liked and respected scientist, there is no mention that any misgivings or failure on the FDA’s part to effectively regulate tobacco products rest to some extent with Dr. Holman. He was, after all, one of the top tobacco leaders at FDA driving those policies and decisions. Your letter indicates that ideas are needed to lift FDA out of its chaotic state…but does not consider that Dr. Holman contributed to it. If Dr. Holman had ideas to innovate viable marketing review pathways and rulemaking, then why did he not implement them while at FDA? Maybe your hopes are not realistic? After all, the Agency looked outside of itself for a new CTP director.

    1. It’s a good point, and I know many feel strongly about this. I have tried to give a view on this point under the objections (C. Ruin the vape industry and join a tobacco company). There is no doubt in my mind that FDA has failed in its mission to competently regulate the vape industry. The question is: how much responsibility does Dr Holman bear for the overall conduct of the bureaucracy he worked in at a senior level? I have tended toward giving the benefit of the doubt. Really, for two reasons: first, bureaucracies have a complex and sometimes overpowering life of their own, and second, it is important to be constructive and to look forward, focussing on what good might come of such a move. But it’s up to him to do good things in the new role and prove his sceptics wrong.

      1. Thomas Gallant

        Perhaps you are right, it may be difficult to know of Dr. Holman’s role at the FDA and his responsibility for policy making -aimed at saving the world from harmful addictive combustibles. Not sure how we can get an answer to that question.

        We could however asked the same question regarding the level of responsibility Big Tobacco/Nicotine has in the failing health, cause of disease and death of zillions of smokers since it was concluded without doubt that the cigarettes worked exactly how they were designed – to addict users and subjecting them to associated risks without their knowledge.

        So – if BT could embrace innovation that would essentially allow them to develop and sell non-addictive combustible tobacco products as a means to break the toxic relationship These companies knowingly created, why wouldn’t you advocate for this?

        You stated that a tobacco company can’t cease to operate because selling cigarettes is its reason for being (even now in the year 2022 with all we know). The company must continue to manufacturer and sell the same types of combustible cigarettes- recipes unchanged- using the exact same product design so smokers can use the drug, nicotine, to maintain their addiction, even though the companies know it will cause harm or kill the consumer if used as intended.

        If the same cigarette companies l sell non-addictive cigarettes to the same consumers, the company is still a cigarette company by your definition, manufacturing and selling cigarettes, and they would also embrace the type of Innovation that you and Dr Holman believe is the means to the intended end- game changer technology.

        Imagine today, all Big Tobacco companies could agree to only sell very low nicotinic content cigarettes/tobacco— presenting three choices to smokers: quit cold turkey; smoke non-addictive cigs to change your relationship with nicotine; or switch to ANDS/ENDS- When a major technology transformation like VLNC tobacco comes to pass- shouldn’t that be celebrated as the ultimate tool to allow consumers who have been wronged for decades, to break their addiction to regular nicotinic content cigarettes and create a new relationship with Nicotine through alternatives? wouldn’t you and the industry embrace the innovation TODAY?

        The companies still will innovate delivery devices for nicotine to retain and grow the legions of nicotine addicts they have been building for decades. If a cigarette company was created to be sustainable through selling cigarettes— until additional R&D for modified risk devices is completed and accepted- this seems like an easy decision?
        All cigarette companies could license very low nicotine tobacco IP to make their own brands of non-addictive cigarettes, so the combustibles they currently sell will be off the market and a person could succeed in leaving their relationship with tobacco behind, and exercise their free will to use an alternative nicotine devices.

        Thankfully these wonderful cigarette companies can continue to exists because they can’t stop being who they are- its perfect role to play… like the arsonist who extinguishes fires.

  2. mike cummings

    This is a nice open letter and lays out the opportunity and the challenges. Of course, it would be useful to know more about why Matt Holman departed FDA. There are many reasons I can think of, but transparency would help. I worry that the change in leadership at CTP signals a new direction away from considering lower risk alternatives. I hope that is not the case, but the recent fiasco with the Juul MDO and then its voluntary pull back at a time when Matt Holman apparently was not involved is concerning to me, because it really challenges FDAs need to stay focused on science, not advocacy.
    I wish Matt Holman well in his new position and hope he can get PMI to be more forthcoming in sharing information on its alternative nicotine products and their potential to displace cigarettes. Data from Japan has been shared to some extent with regards to IQOS, but there are many markets where information has not be made accessible for independent review and comment. PMI gains some much needed credibility in recruiting Matt Holman, lets hope they use it to advance the public health goals they claim to support which in turn will push BAT and other companies to step up their transparency.

    1. Thanks, Mike – I appreciate your comments. It will be a long process at many levels to bring about the necessary transformation, but hopefully, this is another step in the right direction. We need to keep the pressure on.

  3. Dr Andrew Watson MD

    Does vaping reduce disease including addiction from smoking cigarettes, independent and viable info needed or does vaping just lead to a original nonsmoker to smoke ?

    1. Probably the best background for an MD on this is from the 15 former presidents of the Society for Research on Nicotine and Tobacco, published in the American Journal of Public Health last year.

      Balfour, D. J. K., Benowitz, N. L., Colby, S. M., Hatsukami, D. K., Lando, H. A., Leischow, S. J., Lerman, C., Mermelstein, R. J., Niaura, R., Perkins, K. A., Pomerleau, O. F., Rigotti, N. A., Swan, G. E., Warner, K. E., West, R. (2021). Balancing Consideration of the Risks and Benefits of E-Cigarettes. American Journal of Public Health 111(9), 1661–1672.

  4. Dr. Watson, that’s a great question. You’ll have vaping proponents saying nicotine is in itself an essentially benign drug without addictive potential, some will even tout miraculous health benefits. The most successful way to help a smoker quit and maintain cessation is to start by removing the addiction. The FDA’s granting an PMTA and MRTP to 22nd’s VLN product, having been demonstrated to, minimally lead to fewer cigarettes smoked by even smokers not expressing that desire, provides a tool that should be available to all. It eliminates the problems of initial nicotine exposure via vaping, leading to a life long addiction to contend with. Inevitable experimenting by youth with a VLN cigarette would eliminate the addiction problem. Big Tobacco, trying to better its image, has engaged on this CSR ruse. Don’t kid yourself Big Tobacco has always seen the cigarette as the best nicotine delivery device ever. Their very survival is based on nicotine vending. If they have their way they’ll own vaping with its ensured by addiction’s, choice removed, customer base far into the future. Big Tobacco provides major financial support to many if not most vaping advocate groups. By way of disclosure, I am a proud investor of scientifically supported Century 22nd Group XXII.

    1. “Not everybody thinks reducing nicotine in cigarettes to non addictive levels is wrong”

      Actually, I wrote about the sort of problems that could accompany it in “TobakkoNacht!” back in 1997. I made a reference to it as the future fictional 2030’s era President is looking at the concern:

      True, some problems had developed. First of all, the hundreds of billions in expected tax revenue simply disappeared as many smokers showed their true criminal orientation and turned to smuggling or growing their own drugs. Larger basement greenhouses were detected by infrared radiation picked up by AntiBac Copters, but small family operations were hard to find unless helpful neighbors, encouraged by generous head bounties, blew the whistle.

      Unfortunately, standardized USA NoNic cigarettes had never caught on in a big way with the American public. To the small extent that they were sold, they were usually bought by customers who’d then spike them with concentrated nicotine oils smuggled from South America. The number of children who had died as a result of imbibing these concentrated oils, or through smoking homemade cigarettes pumped up to fifty times the normal nicotine level, made the President shiver.
      Perhaps combining concerns about addictive behavior into a single, stronger force might work better? Eliminating caffeine from coffee, sodas, and so-called “energy drinks” could be a significant step forward in keeping impressionable children from addiction. Chocolate could still be a problem, particularly when sweetened with sugar, but taxes and purchase age-regulation based around birth-year could help significantly.

      Or we could just accept the idea that some people enjoy sensations similar to feelings of anticipation and satisfaction that precede and surround a holiday turkey dinner? (OK, that’s a bit U.S.-oriented, but I think most of Clive’s readers will have similar cultural events.)

      – MJM, who’s never smoked a turkey or roasted a cigarette…

      1. Mike Cummings

        Nonsense. The very low nicotine standard is a limit on nicotine in combustible tobacco, there are plenty of other sources of nicotine for those who want and/or need it. In a combustible product the combination of nicotine and toxic smoke make the product unreasonable dangerous, killing 1 in 2 long term users. That is not fiction, it is reality. The very low nicotine standard gives smokers choice since they can chose to smoke for the other factors that cigarette companies claim are so important. Some will choose to use them, but will be able to stop using more easily. We all ought to support free choice not the dictates of companies on maximizing profits regardless of the cost. As for PMI I hope they get out of the cigarette business sooner than later and perhaps Matt Holman can show them a path forward, that is better than the option of the status quo.

      2. Dennis Bruns

        Sounds a lot like the 2000 millennium doomsday prediction fiction. When people came up from their survivalist stocked underground shelters, what do you know, the sun was still shining. Have you marked your calendar to check on the fulfillment of your prophesy? The mandate is coming. Dennis

  5. Hello.
    My own opinion of BT is very very low indeed.
    Holmans departure for his new position is just another opportunity for BT to further their own agenda until they can prove they have changed any and all movement I myself am very suspect of.
    BT Profits over anything at any cost and this goes for the Holman move here.
    These criminals inside BT are like leading Holman even if his intentions are good is like leading leading a lamp to slaughtering. Truly.jk

  6. Dennis Bruns

    Clive what it comes down to, is there’s a lot of science supporting the benefit to a VLN mandate, what scientific evidence can you provide in prove of a nicotine mandate being a misguided approach. There’s a lot of anecdotes comparing failure of previous “light cigarettes” provided by vaping proponents with false assumptions of compensatory smoking. How about some documented science supporting your case against VLN cigarettes as a cessation aid.

    1. If you want a blog to give voice to your VLN obsessions, you can always set one up. These posts are way off-topic, and you are behaving like a spammer.

      My views on VLN are highly sceptical and articulated at some length in a different blog posting.

      The trials you rely on bear no relation to the reality of a market of nicotine-seeking consumers who have to buy these products with actual money. These are about the most useless consumer products imaginable: all the harm of cigarettes and none of the nicotine of a vape.

  7. Daniel Salmon

    I liked your statement:
    Do more to address the tsunami of poor quality and sometimes malicious science that degrades and detracts from addressing the public health challenge. We all have interests in good quality science.

    I urge you to look at all the reputable entities that did studies on VLN cigarettes. Note the names of the various independent professional third parties that oversaw these studies/trials. Also note their findings. The list can be found on 22nd century’s website .
    Daniel Salmon
    Also a science backed 22nd century supporter and investor

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Scroll to Top